Stereotactic Radiotherapy & Image-guided Intensity Modulated Radiotherapy

Status Recruiting

Clinical Trial Summary

Data of 100 patients with spinal metastatic tumor who received stereotactic radiotherapy or conventionally-fractionated image-guided intensity-modulated radiotherapy in the multi-center of the research group from July 2019 to June 2021 will be collected, as well as their follow-up data.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.

Clinical Trial Description

In this study, Data of 100 patients with spinal metastatic tumor who received stereotactic radiotherapy or conventionally-fractionated image-guided intensity-modulated radiotherapy in the multi-center of the research group from July 2019 to June 2021 will be collected, as well as their follow-up data.The metastases were treated with SBRT.Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).The metastases were treated with Conventionally-fractionated image- guided Intensity modulated radiotherapy.Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03963713
Study type	Interventional
Source	Peking University Third Hospital
Contact	Junjie Wang, MD
Phone	+860182264910
Email	junjiewang_edu@sina.cn
Status	Recruiting
Phase	N/A
Start date	June 10, 2019
Completion date	May 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03212742` - Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients	Phase 1/Phase 2
Recruiting	`NCT06190782` - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor	Phase 3
Recruiting	`NCT06120127` - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence	Phase 2
Recruiting	`NCT05176002` - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.	Phase 1/Phase 2
Not yet recruiting	`NCT05909137` - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting	`NCT02661152` - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.	Phase 3
Withdrawn	`NCT02542137` - Abscopal Effect for Metastatic Small Cell Lung Cancer	Phase 2
Completed	`NCT01212731` - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Completed	`NCT01168479` - FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer	Phase 3
Recruiting	`NCT03658343` - T2* MRI Analysis for Sarcoma	N/A
Completed	`NCT03280719` - Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions	N/A
Recruiting	`NCT05515796` - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors	Phase 2
Recruiting	`NCT05514327` - A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL	N/A
Recruiting	`NCT04453826` - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma	Phase 3
Recruiting	`NCT03370926` - FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy	N/A
Active, not recruiting	`NCT03870919` - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients	N/A
Active, not recruiting	`NCT02428049` - Radiation Pneumonitis After SBRT for NSCLC
Recruiting	`NCT04923620` - Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
Active, not recruiting	`NCT05371795` - Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device	N/A
Recruiting	`NCT03210428` - Quantitative MR Imaging in Locally Advanced Cervical Cancer

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Stereotactic Radiotherapy and Image-guided Intensity Modulated Radiotherapy for Spinal Metastatic Tumors — SCIRSM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms